| Liver carcinoma
Tecentriq vs Stivarga
Side-by-side clinical, coverage, and cost comparison for liver carcinoma.Deep comparison between: Tecentriq vs Stivarga with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsStivarga has a higher rate of injection site reactions vs Tecentriq based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Stivarga but not Tecentriq, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Tecentriq
Stivarga
At A Glance
IV infusion
Every 2-4 weeks
PD-L1 antagonist
Oral
Once daily (21 of 28 days)
Multikinase inhibitor
Indications
- Non-Small Cell Lung Carcinoma
- Small cell carcinoma of lung
- Liver carcinoma
- Melanoma
- Alveolar Soft Part Sarcoma
- Metastasis from malignant neoplasm of colon and/or rectum
- Gastrointestinal Stromal Tumors
- Liver carcinoma
Dosing
Non-Small Cell Lung Carcinoma (adjuvant) 840 mg every 2 weeks, 1200 mg every 3 weeks, or 1680 mg every 4 weeks IV for up to 1 year, following resection and up to 4 cycles of platinum-based chemotherapy.
Non-Small Cell Lung Carcinoma (metastatic) 840 mg every 2 weeks, 1200 mg every 3 weeks, or 1680 mg every 4 weeks IV until disease progression or unacceptable toxicity; administer prior to chemotherapy and bevacizumab when given on the same day.
Small cell carcinoma of lung 840 mg every 2 weeks, 1200 mg every 3 weeks, or 1680 mg every 4 weeks IV; administer prior to chemotherapy when given on the same day.
Liver carcinoma 840 mg every 2 weeks, 1200 mg every 3 weeks, or 1680 mg every 4 weeks IV with bevacizumab 15 mg/kg every 3 weeks; administer prior to bevacizumab when given on the same day.
Melanoma Following a 28-day lead-in cycle of cobimetinib and vemurafenib, administer 840 mg every 2 weeks, 1200 mg every 3 weeks, or 1680 mg every 4 weeks IV with cobimetinib 60 mg once daily (21 days on/7 days off) and vemurafenib 720 mg twice daily.
Alveolar Soft Part Sarcoma Adults: 840 mg every 2 weeks, 1200 mg every 3 weeks, or 1680 mg every 4 weeks IV; pediatric patients >=2 years: 15 mg/kg (up to 1200 mg) every 3 weeks IV.
Metastasis from malignant neoplasm of colon and/or rectum, Gastrointestinal Stromal Tumors, Liver carcinoma 160 mg orally once daily for the first 21 days of each 28-day cycle, taken after a low-fat meal; continue until disease progression or unacceptable toxicity.
Contraindications
—
—
Adverse Reactions
Most common (>=20%) Fatigue/asthenia, decreased appetite, nausea, cough, dyspnea (single-agent); fatigue/asthenia, nausea, alopecia, constipation, diarrhea, decreased appetite (combination regimens).
Serious Pneumonia, pneumonitis, sepsis, pyrexia, febrile neutropenia, pulmonary embolism, hepatotoxicity, gastrointestinal hemorrhage.
Postmarketing Pericarditis, pericardial effusion, cardiac tamponade, tenosynovitis.
Most common (>=20%) pain, HFSR/PPES, asthenia/fatigue, diarrhea, decreased appetite/food intake, hypertension, infection, dysphonia, hyperbilirubinemia, fever, mucositis, weight loss, rash, nausea
Serious hepatotoxicity, infections, hemorrhage, gastrointestinal perforation or fistula, dermatological toxicity, hypertension, cardiac ischemia and infarction, reversible posterior leukoencephalopathy syndrome
Postmarketing hypersensitivity reaction, nephrotic syndrome, cardiac failure, arterial aneurysms/dissections/rupture
Pharmacology
Atezolizumab is a PD-L1 antagonist monoclonal antibody that binds to PD-L1 and blocks its interactions with both PD-1 and B7.1 receptors, releasing PD-L1/PD-1-mediated inhibition of the immune response, including activation of the anti-tumor immune response without inducing antibody-dependent cellular cytotoxicity.
Regorafenib is a small molecule inhibitor of multiple membrane-bound and intracellular kinases involved in oncogenesis, tumor angiogenesis, metastasis, and tumor immunity, including VEGFR1-3, KIT, PDGFR-alpha/beta, FGFR1/2, RAF-1, BRAF, and CSF1R.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Tecentriq
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (0/12)
Stivarga
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (0/12) · Qty limit (11/12)
UnitedHealthcare
Tecentriq
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Stivarga
- Covered on 4 commercial plans
- PA (8/8) · Step Therapy (0/8) · Qty limit (7/8)
Humana
Tecentriq
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Stivarga
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Tecentriq.
No savings programs available for Stivarga.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
TecentriqView full Tecentriq profile
StivargaView full Stivarga profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.